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A B S T R A C T
 
Objective: This study was performed to investigate frequency and antimicrobial susceptibility 
of pulmonary pathogens in cystic fibrosis (CF) patients. 
Methods: 129 pediatric patients with CF were enrolled in this cross-sectional study. 
Microbiological cultures were performed based on sputum or pharyngeal swabs. Antibiotic 
susceptibilities of the isolated bacteria were determined by the disk diffusion method. 
Results: The main infecting pathogens were Pseudomonas aeruginosa (38.8%), Klebsiella 
pneumoniae (11.6%) and Staphyloccus areus (9.3%), respectively. The most active antibiotics 
included rifampin (91.7% susceptibility), vancomycin (85%) and imipenem (83.5%). Emerging 
resistance against aminoglycosides was observed.
Conclusion: Regarding in vitro susceptibility results, cyclic treatment of long-term oral 
azithromycin and inhaled tobramycin could prophylactically be applied, and during 
exacerbations, imipenem or ceftazidime in combination with an aminoglycoside such as 
amikacin could be considered the drugs of choice. 
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Introduction
Cystic fibrosis (CF) is the most common autosomal recessive 
lethal pediatric disease caused by mutation in the cystic fibrosis 
transmembrane conductance regulator (CFTR) gene, which 
results in multiple organ failure, and 85% of the mortality is 
due to pulmonary infections.1,2 According to the most accepted 
hypothesis that explains the mechanism underlying respiratory 
infection acquisition in CF patients, defective CFTR results in a 
disturbance in chloride secretion across the apical membrane 
of epithelial cells causing airway surface liquid depletion 
and impaired mucociliary clearance, which leads to bacterial 
colonization.3-5 Despite the polymicrobial nature of CF lung 
infections, Staphylococcus aureus or Haemophilus influenzae are 
often pioneers in colonization. Later on Pseudomonas aeruginosa 
(PA) and other gram-negative non-fermenting organisms, such as 
Stenotrophomonas maltophilia, members of the Burkholderia cepacia-
complex, and Alcaligenes xylosoxidans prevail.3 Biofilm formation 
due to bacterial conversion to mucoidy and inflammation due to 
host inflammatory response result in airway obstruction, which 
is the key cause of morbidity and mortality in CF patients.4 To 
postpone the decline of lung function and prevent the spread of 
antimicrobial resistant pathogens, accurate antibiotic treatment 
strategies are of great importance.6-7 Since there are no published 
data on microbiological surveillance of CF patients from the 
Middle East, this study aims to investigate the frequency and 
antimicrobial susceptibility patterns of bacterial pathogens in CF 
patients admitted to the Mofid Children’s Hospital, Tehran, Iran 
during a six-year-period.
Materials and methods
Patients and samples
129 pediatric patients with CF who had acute exacerbation and 
were hospitalized in the Mofid Children’s Hospital, from 2004 to 
2010 were enrolled in this cross-sectional study. Diagnosis of CF 
was performed according to guidelines recommended by the Cystic 
Fibrosis Foundation Consensus.8 Data on gender, age of diagnosis, 
age of first exacerbation, age at admission, and hospitalization 
period were gathered based on a questionnaire and on a review of 
patients’ medical records. This study was approved by the Shahid 
Beheshti University of Medical Sciences’ Ethical Committee and an 
informed consent was obtained from the patients’ parents.
Microbiological cultures
During exacerbation, sputum samples or pharyngeal swabs 
were obtained and cultured on agar medium for 48 hours at 
37°C. The dominant bacteria grown for each patient sample 
were isolated and identified by standard biochemical tests.9
Statistical analysis
To compare differences between age, gender and culture based 
groups of the patients, a non-parametric statistical analysis 
was performed using the two-tailed Mann Whitney U test and 
the Kruskal-Wallis test, allowing for continuous variables 
and non-normal distribution. 
Susceptibility tests
Susceptibility of the isolated bacteria to 29 antibiotics (Mast 
Diagnostics – UK), shown in Fig. 1, was performed by disk 
diffusion technique according to the CLSI criteria.10
Results
Among the 129 CF patients, 51 (39.5%) were female and 78 (60.5%) 
were male. The mean (± SD) age of the patients was 75.57 (± 6 
2.48) months; the median age was 63 months with the age 
range of 4-215 months. The average age at diagnosis, age of 
first exacerbation and age at admission were 4.95, 9.3 and 75.57 
months, respectively. Demographic data of the patients are shown 
in Table 1. There was no significant difference between female 
and male groups in age at admission, age of first exacerbation 
and age at diagnosis, as well as rate of PA colonization (two-
tailed Mann-Whitney U test, p > 0.05). Hospitalization period was 
12.2 days on average, and significant difference was observed in 
hospitalization periods between patients who had positive cultures 
and patients with negative cultures (10.44 vs. 12.62 days, two-tailed 
Mann-Whitney U test, p < 0.05). Among culture positive patients, 
the hospitalization period was significantly longer in patients 
infected with PA compared to other microorganisms (13.28 vs. 
11.5, two-tailed Mann Whitney U test, p < 0.05). 123 bacterial 
and six fungal strains were isolated and characterized. In 24% 
of the patients, no microorganisms were isolated and 24% of the 
patients were infected by more than one species. Patients were 
sub-divided by age: under or equal to 24 months (32.6%), 24 to 
60 months (49.6%), and over 60 months (50.4%). Differences in 
bacterial colonization by age groups are demonstrated in Fig. 2. 
 Variable (unit) Range Mode SD Mean
Age at admission (months) 4-215 11 63 62.5 75.6
Age of first exacerbation (months) 1-120 1 4 19.3 9.3
Age at diagnosis (months) 3-6 6 5 1.16 4.95
Hospitalization period (days) 3-21 10 12 4.1 12.2
SD, standard deviation.
Table 1 – Demographic findings of enrolled CF patients in this study
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Fig. 1 – Rate of in vitro susceptibility (%) of Pseudomonas aeruginosa isolates against different antibiotics.
Fig. 2 – Frequencies of negative and positive cultures for each microorganism based on age groups.
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Overall, PA was isolated as the most prevalent germ. Among 
patients under two years of age, K. pneumoniae was the most 
frequently isolated bacteria, and among patients over two 
years of age, PA. The main infecting pathogens were PA (38.8%), 
Klebsiella pneumoniae (11.6%), Staphyloccus areus (9.3%), Escherichia 
coli (6.2%) and Streptococcus pneumoniae (5.4%), respectively. In 
total, colonization rate was significantly age-related: 78.6% 
in patients under the age of two years, 71.9% in patients under 
the age of five years, and 89.2% in patients over the age of five 
years (Kruskal-Wallis test, p < 0.01). It was observed that as 
the age of patients increased, colonization rate of PA, S. aureus, 
S. pneumoniae and Acinetobacter spp. increased, and the frequency 
of K. pneumoniae decreased. The colonization rate of PA was 
19% in patients younger than 2 years of age, 23.4% in patients 
younger than five years of age and 53.8% in patients older than 
five years of age. Fungi were isolated only from patients older 
than two years of age and some microorganisms, including 
B. cepacia-complex and Enterococcus spp. were only detected 
in patients older than five years of age (Fig. 2). Antibiotic 
susceptibility results of the three most prevalently isolated 
bacteria are shown in Figs. 1, 3 and 4. Differences in the rate 
of in vitro resistance to antibiotics and the rate of in vitro 
Fig. 3 – Rate of in vitro susceptibility (%) of Klebsiella pneumoniae isolates against different antibiotics.
Fig. 4 – Rate of in vitro susceptibility (%) of Staphylococcus aureus isolates against different antibiotics.
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Fig. 5 – Rate of in vitro antibiotic resistance based on age groups of the patients.
susceptibility to antibiotics by age groups are demonstrated 
in the Figs. 5 and 6, respectively. The most active antibiotics 
included rifampin (91.67% susceptibility), vancomycin (85%), 
imipenem (83.54%), ciprofloxacin (79.49%), ofloxacin (75.86%), 
ceftazidime (67.82%) and azithromycin (61.22%) and the less 
active antibiotics were penicillin (97.87% resistance), ampicillin 
(95.56%), cephalothin (92%), oxacilin (89.13%) and cefixime 
(86.9%), respectively. Among various identified bacteria, E. coli, 
PA, K. pneumoniae, S. aureus, and Enterococcus spp. exhibited the 
highest antimicrobial resistance, respectively. 
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Fig. 6 – Rate of in vitro antibiotic susceptibility based on age groups of the patients.
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Discussion
Several previous studies have evaluated the microbiology 
of pulmonary infections in patients with CF, but there have 
been no studies on this subject from the Middle East.11-14 
In this study, we aimed to survey pulmonary infections of 
CF patients from the Middle East, specifically from Iran. 
In contrast to some studies that have reported female 
gender as a risk factor for colonization of PA in CF patients, 
we found no significant difference in PA colonization 
between gender groups in our patients.15-16 Although the 
colonization rate of PA among our patients (38.8%) was less 
than the overall percentage reported by the Cystic Fibrosis 
Foundation, USA, in 2006 (55.0%), in accordance with other 
reports, we detected PA as the most prevalent pulmonary 
pathogen in our CF patients, mainly in older children and 
caused longer hospitalization periods.2-3,17 According to 
data from the Cystic Fibrosis Foundation (USA) in 2006, 
the initial PA colonization often occurs in patients with 
CF under the age of 6 years and increasing age is a risk 
factor for PA infection in CF patients.2 The same results 
were obtained in our study – colonization rate of PA was 
19% among patients younger than two years of age and 
23.4% among patients younger than five years of age, which 
was increased to 53.8% in patients older than five years of 
age. There is paucity of reports regarding colonization of 
K. pneumoniae in CF patients which was the second most 
prevalent microorganism isolated from our patients.18,19 
In agreement with other reports, S. aureus was one of the 
prevailing isolated bacteria in our study. Conflicting with 
reports that have detected S. aureus as one of the first 
bacteria infecting pediatric patients with CF, in our study 
S. aureus was more common among patients over two 
years of age.3,6 Recent studies have reported the advent of 
S. pneumoniae as a resistant pathogen in CF patients.20,21 
Although in our study S. pneumoniae showed a higher 
frequency than its common frequency (3-5%), it was the 
most susceptible germ among the investigated bacteria 
(data not shown).22 Some pathogens such as H. influenzae, 
S. maltophilia and A. xylosoxidans have been recently 
detected more frequently in CF patients, which could be 
considered as a result of modern therapies.12,13 In our 
study, these microorganisms were not frequent, perhaps 
because of the traditional therapies that have been applied 
to our patients. 
Regarding in vitro23 
Although in our study rifampin was shown to be the most 
active antibiotic, resistance to rifampin was found among 
a few S. aureus isolates. Recent concerns have been raised 
about the emergence of heteroresistant vancomycin-
intermediate S. aureus (hVISA) and vancomycin-resistant 
Streptococcus (VRS).24,25 In our study, all S. pneumoniae isolates 
were sensitive to vancomycin, but some isolates of S. aureus 
appeared to be intermediate. Except for K. pneumoniae 
and S. pneumoniae isolates, all of which were sensitive to 
imipenem. Resistance against imipenem among three other 
prevalent bacteria (remarkably so in PA) could be considered 
as a confirmation for increasing resistance against this 
antibiotic among CF patients.26 Ciprofloxacin, ceftazidime 
and azithromycin have been recommended as therapies for 
PA eradication in CF patients.27 Because of relative in vitro 
resistance observed against these antibiotics among our 
PA isolates, if one of them was not effective on a patient, 
another could be applied as second-line therapeutic agent. 
Inhaled tobramycin is a front-line aminoglycoside used 
successfully for early eradication of PA.22 Because of the 
emerging resistance to tobramycin observed in our study, 
the maintenance of its clinical benefits depends on its 
chronic and cyclic use, as reported by other studies.27-28 In 
total, in vitro decrease of the formation of biofilms by quorum 
sensing disruption, modulation of the host inflammatory 
response, reduction in sputum viscosity, and enhancement 
of sputum clearance were discussed in a previous study, 
and in agreement with another long-term study, oral 
azithromycin may cause improvement in respiratory 
function in CF patients.29,30 Conflicting to a recent study 
that reported treatment with azithromycin for 24 weeks 
resulting in no improvement in pulmonary function of CF 
patients uninfected with PA, in our study azithromycin was 
one of the most active antibiotics in vitro, not only against 
PA isolates but also against other isolated respiratory 
pathogens;31 and activities of macrolides were greater than 
aminoglycosides. Among macrolides, azithromycin was 
the most active antibiotic in vitro. Due to positive effects of 
macrolides on susceptibility results, rifampin is a typical 
treatment of S. aureus infections in CF patients.
Because of the high frequency of PA among our patients, 
a policy of segregating patients to prevent epidemic strain 
transmission is recommended.21 Although the clinical rel-
evance of in vitro antimicrobial susceptibility of bacterial 
pathogens involved in CF pulmonary infections has been 
questioned, as there are no clear alternatives, based on our 
in vitro results we assume that oral azithromycin and 
nebulized tobramycin could be effective if used in a cyclic 
fashion as a long-term prophylaxis, and in cases of resist-
ance, an off-period for these antibiotics should be applied.22 
During exacerbations, imipenem or ceftazidime in com-
bination with an aminoglycoside such as amikacin could 
be drugs of choice that rely on clinical responses of the 
patients, and in cases of gram positive infections, rifampin 
could be added.
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